Opioids such as morphine numb pain but often concomitantly induce itch. Liu et al. (2011) now separate the sensation of itch from opioid-induced analgesia, showing that in a subset of spinal neurons, morphine directly induces itch by signaling through a heteromer of opioid-and itch-mediating G protein-coupled receptors.
Itch, or pruritus, is defined as an unpleasant sensation that elicits the desire or reflex to scratch (Ikoma et al., 2006) . Itch occurs under many pathological conditions, such as atopic dermatitis, and is a common side effect of many drugs, including antibiotics, antifungal drugs, and narcotic pain medications (Reich et al., 2009) . For example, the malaria drug chloroquine induces itch by acting on peripheral sensory neurons via a G protein-coupled receptor, MrgprA3 ). Another example is opioidinduced itch, which is most severe when opioids are administered directly into the spinal column via an epidural injection. Spinal opioid-induced itch has been assumed to arise as a consequence of pain inhibition, but the underlying mechanism has been largely unknown. In this issue of Cell, a study by Liu et al. provides compelling evidence that spinal opioidinduced itch is evoked independently of opioid-induced analgesia by signaling through an opioid receptor splice isoform expressed in itch-mediating spinal neurons (Liu et al., 2011) .
The distinct sensations of itch and pain are evoked by different stimuli and induce discrete responses (scratching versus withdrawal). However, interactions between these two sensations are well known; various types of noxious stimuli are able to inhibit itch, and inhibition of pain may evoke itch (Ikoma et al., 2006) . It has been postulated that pain signals have a dominant inhibitory effect on itch signals. This selectivity model is supported by recent studies reporting attenuated pain and enhanced itch behaviors in mice whose neurotransmission is inactivated in subsets of nociceptive sensory neurons (Patel and Dong, 2010) . As the selectivity model predicts, opioidinduced itch has been thought to arise indirectly as a consequence of opioidinduced analgesia.
The new study by Liu et al. explores the molecular basis of morphine-induced scratching (MIS) and analgesia (MIA) in mice. Previous experiments had established that both MIS and MIA are mediated by m-opioid receptor (MOR) (Loh et al., 1998; Matthes et al., 1996) . The mouse Oprm gene encodes many splice isoforms of MOR (Pan, 2005) . Liu and colleagues used exon-specific siRNA knockdown in vivo and identified MOR1D and MOR1 isoforms to be specifically required for itch and analgesia, respectively. MOR1D is coexpressed with the gastrinreleasing peptide receptor (GRPR), a G protein-coupled receptor that marks spinal cord neurons required for the sensation of itch (Sun and Chen, 2007; Sun et al., 2009 ). Both pharmacological and genetic knockdown of GRPR resulted in specific attenuation of MIS without affecting MIA (Figure 1 ). The authors show that MOR1D and GRPR physically interact. Upon further investigation, they provide functional evidence that these two receptors cross-activate in only one direction: MOR1D activation by morphine results in GRPR activation, but not vice versa. Providing potential therapeutic insight, Liu and colleagues show that a unique C-terminal peptide of MOR1D attached to a plasma membrane-permeating signal competes with endogenous MOR1D for physical interaction with GRPR. Spinal administration of this synthetic peptide attenuates MIS without affecting MIA, indicating that MOR1D-GRPR cross-activation is required for spinal opioid-induced itch.
Liu et al. convincingly demonstrate a direct role of opioid receptors in itch signaling but cannot exclude the possibility that other indirect mechanisms also mediate opioidinduced itch. The new insights gained from this study about the relationship between pain and itch raise important questions. What is the mechanism behind the unidirectional cross-activation of the MOR1D-GRPR complex; what is the role of MOR1D in other locations, such as in the peripheral nervous system and in the brain; and why is opioid signaling linked to itch? Is the itch-inducing pathway only relevant at clinical but not endogenous doses of opioids? One possibility, as proposed by the authors, is that the unpleasant opioid-associated itching sensation might serve as a warning signal, protecting the body from potential opiate overdose (due to external sources or metabolic disorders that cause increased endogenous opioids). However, this model does not seem in accord with the antipruritic effect of k-opioids (Ikoma et al., 2006) , and it is not clear how a feedback signal from itch would benefit metabolic disorders. In vivo comparisons between MOR1D and MOR1 sensitivities to physiological concentration of opioids may shed light on the physiological relevance of the MOR1D pathway. MOR1D isoform-specific conditional knockouts would also be very valuable for studies in pruritus and beyond.
This study offers the possibility to develop a novel therapeutic strategy to specifically attenuate itch without affecting the analgesic efficacy of opioids. When opioids are spinally administered, 60%-90% of patients are affected by itch. Current therapeutics against opioidinduced itch are mostly opioid receptor antagonists that also attenuate analgesic effect (Reich et al., 2009 ). The authors propose that blocking MOR1D-GRPR heterodimerization is a highly specific way to attenuate opioid-induced itch. Indeed, they demonstrate the viability of this approach using a synthetic peptide administered intrathecally. This is a logical albeit challenging strategy, as very few approved drugs specifically target protein-protein interactions. As an alternative, many of the molecular components in the opioid-induced itch pathway, including GRPR, PLCb, and IP3R3, may be additional candidate targets for specifically attenuating itch.
